UroGen Pharma Ltd. - Ordinary Shares (URGN)

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.

This clinical-stage biotech develops therapies for CML, NASH, and obesity.

UroGen (URGN) Q4 2025 Earnings Call Transcript

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

UroGen (URGN) Q3 2025 Earnings Call Transcript

UroGen Q3 2025 results show a revenue miss but a narrower-than-expected loss. The biopharma highlighted strong pipeline progress and the ongoing launch of its new product, ZUSDURI.

UroGen Pharma (URGN) reported Q2 2025 revenue of $24.2M, beating estimates, but EPS missed at -$1.05. JELMYTO sales grew 11% YoY, while ZUSDURI launch and R&D costs widened losses. Shares dipped pre-market.

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

U.S. stock futures were trading higher on Monday following Friday's sharp declines. Futures of benchmark indices were higher in premarket.

UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.